AI and Digital Tools Transform Clinical Trial Feasibility, Site Selection, and Pharmacy Operations
AI-driven feasibility tools are cutting clinical trial site selection timelines from months to weeks by analysing historical data, enrolment benchmarks, and geographic trends. Clinical trial pharmacy software platforms are integrating with management systems and incorporating AI, machine learning, and blockchain to improve medication tracking, regulatory compliance, and data security across global trials.
Artificial intelligence and advanced software platforms are rapidly reshaping how clinical trials are planned, executed, and managed, addressing long-standing challenges in feasibility, site selection, and medication management.
Clinical trial feasibility studies — which evaluate whether a trial can be successfully conducted at a specific site by considering patient population, resources, and timelines — typically take one month to complete. Feasibility and site selection remain among the most significant drivers of timeline delays and budget overruns in clinical development. However, sponsors are increasingly turning to integrated, AI-driven approaches that are transforming feasibility from a manual, assumption-based process into a more strategic, evidence-informed model.
AI models can analyse historical studies, enrolment benchmarks, and operational trends to identify eligibility criteria or study design assumptions that may unnecessarily limit recruitment or create operational burden for sites. By connecting protocol requirements with historical trial performance, real-world treatment patterns, and site and investigator data, AI can help sponsors identify higher-potential sites, improve enrolment predictability, and accelerate study startup timelines. This approach is helping reduce the feasibility process from months to weeks, allowing sponsors to get new therapeutics to market faster.
AI-powered feasibility tools offer several specific capabilities. They can generate protocol-aware site recommendations by analysing protocol criteria and historical data to produce targeted shortlists of sites already treating relevant patient populations. They can streamline the distribution, collection, and analysis of feasibility assessments, reducing reliance on spreadsheets and email chains. Enrolment forecasting models assess historical enrolment rates, competing studies, geographic trends, and patient availability to better predict which sites are most likely to enrol successfully and stay on target. By incorporating real-world demographic and epidemiological data, these tools can also help sponsors identify sites with access to more representative patient populations.
Historically, feasibility assessments often required teams to manually review protocols, aggregate competitive trial information, analyse historical enrolment patterns, and coordinate across multiple vendors and internal stakeholders — a process that could take weeks. AI can now synthesise many of these inputs in minutes, helping sponsors quickly understand where eligible patients are being treated, which investigators have relevant experience, and whether enrolment assumptions are realistic.
On the medication management side, clinical trial pharmacy software has become an essential tool for managing the tracking and dispensing of investigational drugs. These platforms are being designed to facilitate the dispensing and management of investigational drugs and the comprehensive monitoring of supply chains, inventory management, and patient-specific medication regimens. Data-driven insights from these platforms play a critical role in reducing the risk of errors, ensuring the correct drug is administered to the right patient, and preventing costly trial delays due to medication shortages or mismanagement.
Increasingly, clinical trial pharmacy software interfaces with other clinical trial management systems, including Clinical Trial Management Systems (CTMS) and Electronic Data Capture (EDC) systems. From patient recruitment and medication tracking to final data analysis, this interconnection coordinates every facet of the experiment, reducing the risk of data silos and improving the overall accuracy of trial outcomes.
Regulatory compliance remains a significant challenge in this space. Strict restrictions apply to clinical trials, and pharmacy software must conform with national and international standards such as those established by the FDA and EMA. Software must be able to track every dose dispensed, ensure accurate labeling, and protect patient confidentiality and data integrity. As clinical trials become more global, software must also be adaptable enough to handle varying regulations, standards, and supply chain processes across multiple countries.
Innovation is addressing these challenges. AI and machine learning are being used to automate and streamline manual processes, optimise medication dispensing, and even predict supply chain disruptions before they happen. These technologies can analyse vast amounts of data in real time, offering insights into patient adherence, medication use, and potential adverse reactions. Additionally, blockchain technology is being integrated into pharmacy software to enhance data security and transparency, ensuring that trial data is immutable and resistant to tampering.
From the site perspective, AI-driven tools help eliminate repetitive feasibility surveys and reduce time spent pursuing trials that are not a good fit. Sites gain greater visibility into sponsor demand, enabling them to showcase their capabilities, highlight availability, and connect with more relevant, better-matched study opportunities.